Blood cancer patients may get liver protection from common drug

NCT ID NCT07476885

Not yet recruiting Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This real-world study looks at whether polyene phosphatidylcholine injection can prevent or treat drug-induced liver injury in adults with blood cancers like leukemia and lymphoma. Researchers will review medical records of 1,000 patients to see how well the drug works and if it is safe. The main focus is on liver enzyme improvement after one week of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: polyene phosphatidylcholine injection
What this could lead to: If successful, this could show that polyene phosphatidylcholine is a safe and effective option to protect the liver during chemotherapy for blood cancers.
What could go wrong: This is an observational study looking back at medical records, not a controlled trial, so results may be less reliable. It is also early-stage and may not prove the drug works better than other options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG INDUCED LIVER INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm drug-induced liver injury prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG INDUCED LIVER INJURY

More trials for these conditions

Other studies related to the condition(s) this trial covers.